Adela (formerly DNAMx), a Toronto, Canada-based company which specializes in detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test, raised $60M in Series A funding.
The round was led by F-Prime Capital with participation from OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management.
The company plans to to use the advance its technology towards commercialization, with initial applications across the cancer care continuum from early detection to disease monitoring. In the future, the company plans to apply the technology to other disease states, leveraging the genome-wide approach to enable expansion to other conditions.
Led by Scott Bratman, MD, PhD, Chief Executive Officer, and Daniel De Carvalho, PhD, Chief Scientific Officer, Adela has the mission to enable the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome. The company’s genome-wide methylation enrichment technology offers the potential to detect many diseases with a single assay at scale, with best-in-class performance.
The founding members of the Adela team are:
- Scott Bratman, MD, PhD, Chief Executive Officer and President: Internationally recognized expert in cell-free DNA, co-inventor of CAPP-Seq liquid biopsy technology
- Daniel De Carvalho, PhD, Chief Scientific Officer: World-leading scholar in cancer epigenetics, inventor of Adela’s proprietary platform
- Anne-Renee Hartman, MD, Chief Medical Officer: Pioneer in the field of cancer early detection, former Head of Clinical Development & Medical Affairs at GRAIL
- Todd Arnold, PhD, Chief Operating Officer: Seasoned Laboratory and R&D operations executive, former Chief Laboratory Operations Officer at Sema4
- David Scheer, Board Chair: Founder, Director, and/or Chairman of more than 10 life science companies
- Maneesh Jain, PhD, Board Member: CEO, Founder, and/or Director of six life science start-ups including Cirina, the first liquid biopsy company for early cancer detection
FinSMEs
30/06/2021